Quantitative profiling of tyrosine phosphorylation revealed changes in the activity of the T cell receptor signaling pathway upon cisplatin-induced apoptosis

Journal of Proteomics

Volumn 91, Issue , 2013, Pages 344-357

  Størvold, Gro L ^a   Landskron, Johannes ^a   Strozynski, Margarita ^a   Arntzen, Magnus Ø ^a   Koehler, Christian J ^a   Kalland, Maria E ^a   Taskén, Kjetil ^a,b   Thiede, Bernd ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apoptosis; Cisplatin; Fluorescent cell barcoding; Phospho flow cytometry; Phosphotyrosine; T cell receptor signaling pathway

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE LCK; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR;

APOPTOSIS; ARTICLE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE PHOSPHODIESTERASE GAMMA-1; 7-AAD; 7-AMINO-ACTINOMYCIN D; ACTIVATING TRANSCRIPTION FACTOR 2; APOPTOSIS; ATF2; C-TERMINAL SRC KINASE; CISPLATIN; CSK; ERK; EXTRACELLULAR-SIGNAL-REGULATED KINASE; FCB; FLUORESCENT CELL BARCODING; FORWARD SCATTER; FSC; GAPDH; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; IL-2; IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF; INTERLEUKIN-2; INTERLEUKIN-2-INDUCIBLE T-CELL KINASE; ITAM; ITK; LAT; LCK; LINKER FOR ACTIVATION OF T-CELLS; MAPK; MAPK-ACTIVATED PROTEIN KINASE 2; MAPK/ERK KINASE; MAPKAPK2; MEDIAN FLUORESCENT INTENSITY; MEK; MFI; MITOGEN-ACTIVATED PROTEIN KINASE; PHOSPHO-FLOW CYTOMETRY; PHOSPHOTYROSINE; PLCΓ1; SH2 DOMAIN-CONTAINING LEUKOCYTE-SPECIFIC PROTEIN OF 76KDA; SIDE SCATTER; SILAC; SLP76; SSC; STABLE ISOTOPE LABELING WITH AMINO ACIDS IN CELL CULTURE; T CELL RECEPTOR; T CELL RECEPTOR SIGNALING PATHWAY; TCR; TYROSINE-PROTEIN KINASE LCK/LEUKOCYTE C-TERMINAL SRC KINASE; TYROSINE-PROTEIN KINASE ZAP-70/ZETA-CHAIN-ASSOCIATED PROTEIN OF 70KDA; ZAP70;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CISPLATIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEOMICS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TYROSINE;

EID: 84883197055     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.07.019     Document Type: Article

References (52)

1. Preisinger C., von Kriegsheim A., Matallanas D., Kolch W. Proteomics and phosphoproteomics for the mapping of cellular signalling networks. Proteomics 2008, 8:4402-4415.
2. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
3. Cargnello M., Roux P.P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011, 75:50-83.
4. White F.M. Quantitative phosphoproteomic analysis of signaling network dynamics. Curr Opin Biotechnol 2008, 19:404-409.
5. Boersema P.J., Foong L.Y., Ding V.M., Lemeer S., van Breukelen B., Philp R., et al. In-depth qualitative and quantitative profiling of tyrosine phosphorylation using a combination of phosphopeptide immunoaffinity purification and stable isotope dimethyl labeling. Mol Cell Proteomics 2010, 9:84-99.
6. Krutzik P.O., Nolan G.P. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006, 3:361-368.
7. Oberprieler N.G., Lemeer S., Kalland M.E., Torgersen K.M., Heck A.J., Tasken K. High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells. Blood 2010, 116:2253-2265.
8. Mann M., Ong S.E., Gronborg M., Steen H., Jensen O.N., Pandey A. Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol 2002, 20:261-268.
9. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
10. Kruger M., Kratchmarova I., Blagoev B., Tseng Y.H., Kahn C.R., Mann M. Dissection of the insulin signaling pathway via quantitative phosphoproteomics. Proc Natl Acad Sci U S A 2008, 105:2451-2456.
11. Bose R., Molina H., Patterson A.S., Bitok J.K., Periaswamy B., Bader J.S., et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U S A 2006, 103:9773-9778.
12. Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 2005, 23:94-101.
13. Harsha H.C., Pandey A. Phosphoproteomics in cancer. Mol Oncol 2010, 4:482-495.
14. Basu A., Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids 2011, [Article ID 201367].
15. Rebillard A., Lagadic-Gossmann D., Dimanche-Boitrel M.T. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem 2008, 15:2656-2663.
16. Brozovic A., Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007, 251:1-16.
17. Li X.B., Schluesener H.J. Therapeutic effects of cisplatin on rat experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp (Warsz) 2006, 54:51-53.
18. Sfikakis P.P., Souliotis V.L., Katsilambros N., Markakis K., Vaiopoulos G., Tsokos G.C., et al. Downregulation of interleukin-2 and apha-chain interleukin-2 receptor biosynthesis by cisplatin in human peripheral lymphocytes. Clin Immunol Immunopathol 1996, 79:43-49.
19. Kouchi Y., Maeda Y., Ohuchida A., Ohsawa M. Immunotoxic effect of low dose cisplatin in mice. J Toxicol Sci 1996, 21:227-233.
20. Thiede B., Rudel T. Proteome analysis of apoptotic cells. Mass Spectrom Rev 2004, 23:333-349.
21. Arntzen M.O., Thiede B. ApoptoProteomics, an integrated database for analysis of proteomics data obtained from apoptotic cells. Mol Cell Proteomics 2012, 11. [M111.010447].
22. Schmidt F., Hustoft H.K., Strozynski M., Dimmler C., Rudel T., Thiede B. Quantitative proteome analysis of cisplatin-induced apoptotic Jurkat T cells by stable isotope labeling with amino acids in cell culture, SDS-PAGE, and LC-MALDI-TOF/TOF MS. Electrophoresis 2007, 28:4359-4368.
23. Solstad T., Bjorgo E., Koehler C.J., Strozynski M., Torgersen K.M., Tasken K., et al. Quantitative proteome analysis of detergent-resistant membranes identifies the differential regulation of protein kinase C isoforms in apoptotic T cells. Proteomics 2010, 10:2758-2768.
24. D'Aguanno S., D'Alessandro A., Pieroni L., Roveri A., Zaccarin M., Marzano V., et al. New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation. J Proteome Res 2011, 10:416-428.
25. Castagna A., Antonioli P., Astner H., Hamdan M., Righetti S.C., Perego P., et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004, 4:3246-3267.
26. Le M.K., Lincet H., Deslandes E., Hubert-Roux M., Lange C., Poulain L., et al. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 2006, 6:5183-5192.
27. Ge F., Xiao C.L., Bi L.J., Tao S.C., Xiong S., Yin X.F., et al. Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells. PLoS One 2010, 5:e13095.
28. Gerner C., Frohwein U., Gotzmann J., Bayer E., Gelbmann D., Bursch W., et al. The Fas-induced apoptosis analyzed by high throughput proteome analysis. J Biol Chem 2000, 275:39018-39026.
29. Schmidt F., Strozynski M., Salus S.S., Nilsen H., Thiede B. Rapid determination of amino acid incorporation by stable isotope labeling with amino acids in cell culture (SILAC). Rapid Commun Mass Spectrom 2007, 21:3919-3926.
30. Olsen J.V., de Godoy L.M., Li G., Macek B., Mortensen P., Pesch R., et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics 2005, 4:2010-2021.
31. Koehler C.J., Strozynski M., Kozielski F., Treumann A., Thiede B. Isobaric peptide termini labeling for MS/MS-based quantitative proteomics. J Proteome Res 2009, 8:4333-4341.
32. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008, 26:1367-1372.
33. Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567.
34. Barsnes H., Vizcaino J.A., Eidhammer I., Martens L. PRIDE Converter: making proteomics data-sharing easy. Nat Biotechnol 2009, 27:598-599.
35. Bull V.H., Fargestad E.M., Strozynski M., Thiede B. Temporal proteome profiling of taxol-induced mitotic arrest and apoptosis. Electrophoresis 2010, 31:1873-1885.
36. Salmond R.J., Filby A., Qureshi I., Caserta S., Zamoyska R. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 2009, 228:9-22.
37. Couture C., Songyang Z., Jascur T., Williams S., Tailor P., Cantley L.C., et al. Regulation of the Lck SH2 domain by tyrosine phosphorylation. J Biol Chem 1996, 271:24880-24884.
38. Huang Y., Wange R.L. T cell receptor signaling: beyond complex complexes. J Biol Chem 2004, 279:28827-28830.
39. Tai W.T., Cheng A.L., Shiau C.W., Huang H.P., Huang J.W., Chen P.J., et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 2011, 55:1041-1048.
40. Riha P., Rudd C.E. CD28 co-signaling in the adaptive immune response. Self Nonself 2010, 1:231-240.
41. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008, 9:231-241.
42. Winograd-Katz S.E., Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 2006, 25:7381-7390.
43. Samelson L.E. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol 2002, 20:371-394.
44. Andreotti A.H., Schwartzberg P.L., Joseph R.E., Berg L.J. T-cell signaling regulated by the Tec family kinase Itk. Cold Spring Harb Perspect Biol 2010, 2:a002287.
45. Rincon M., Davis R.J. Regulation of the immune response by stress-activated protein kinases. Immunol Rev 2009, 228:212-224.
46. Mittelstadt P.R., Salvador J.M., Fornace A.J., Ashwell J.D. Activating p38 MAPK: new tricks for an old kinase. Cell Cycle 2005, 4:1189-1192.
47. Losa J.H., Parada C.C., Viniegra J.G., Sanchez-Arevalo Lobo V.J., Cajal S., Sanchez-Prieto R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003, 22:3998-4006.
48. Mansouri A., Ridgway L.D., Korapati A.L., Zhang Q., Tian L., Wang Y., et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003, 278:19245-19256.
49. Olson J.M., Hallahan A.R. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004, 10:125-129.
50. Koo M.S., Kwo Y.G., Park J.H., Choi W.J., Billiar T.R., Kim Y.M. Signaling and function of caspase and c-jun N-terminal kinase in cisplatin-induced apoptosis. Mol Cells 2002, 13:194-201.
51. Krilleke D., Ucur E., Pulte D., Schulze-Osthoff K., Debatin K.M., Herr I. Inhibition of JNK signaling diminishes early but not late cellular stress-induced apoptosis. Int J Cancer 2003, 107:520-527.
52. Abraham R.T., Weiss A. Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol 2004, 4:301-308.